CA3224774A1 - Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis - Google Patents

Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis Download PDF

Info

Publication number
CA3224774A1
CA3224774A1 CA3224774A CA3224774A CA3224774A1 CA 3224774 A1 CA3224774 A1 CA 3224774A1 CA 3224774 A CA3224774 A CA 3224774A CA 3224774 A CA3224774 A CA 3224774A CA 3224774 A1 CA3224774 A1 CA 3224774A1
Authority
CA
Canada
Prior art keywords
nlrp3 inhibitor
compound
nlrp3
inhibitor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3224774A
Other languages
English (en)
French (fr)
Inventor
Laura COLEMAN
Christopher Farady
Ewa GATLIK
Matthias Schieker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3224774A1 publication Critical patent/CA3224774A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3224774A 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis Pending CA3224774A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163224890P 2021-07-23 2021-07-23
US63/224,890 2021-07-23
PCT/IB2022/056695 WO2023002399A1 (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
CA3224774A1 true CA3224774A1 (en) 2023-01-26

Family

ID=82846336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3224774A Pending CA3224774A1 (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Country Status (8)

Country Link
US (1) US20250082611A1 (https=)
EP (1) EP4373489A1 (https=)
JP (1) JP2024525897A (https=)
KR (1) KR20240038995A (https=)
CN (1) CN117693340A (https=)
CA (1) CA3224774A1 (https=)
IL (1) IL309085A (https=)
WO (1) WO2023002399A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN112654350A (zh) * 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment

Also Published As

Publication number Publication date
WO2023002399A1 (en) 2023-01-26
JP2024525897A (ja) 2024-07-12
KR20240038995A (ko) 2024-03-26
EP4373489A1 (en) 2024-05-29
IL309085A (en) 2024-02-01
CN117693340A (zh) 2024-03-12
US20250082611A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US12201634B2 (en) Methods of treating depression using orexin-2 receptor antagonists
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
NO20171934A1 (en) Compositions and methods of treating a neurodegenerative disease
JP2022105159A (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
US20250082611A1 (en) Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis
JP2024500874A (ja) がんを処置する方法
JP2024500877A (ja) がんを処置する方法
JP2024504002A (ja) がんを処置する方法
TW201625244A (zh) 壓力性疾病之預防及／或治療用醫藥
WO2021079983A1 (ja) 軟骨保護用の医薬組成物
CN104066323A (zh) 用于治疗患者亚群中痛风的方法
US20220194930A1 (en) Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same
JP2025527188A (ja) Ｎｌｒｐ３阻害剤の投与計画
JP2005336174A (ja) 変形性関節症治療剤
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
WO2025068958A1 (en) Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases
US20090156609A1 (en) Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds
JPWO2017119455A1 (ja) 自閉症スペクトラム障害の予防または治療剤
CN116648445A (zh) 治疗或预防慢性肾脏病的方法
Sevilla Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies
KR20190140011A (ko) 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法
HK40096745A (zh) 治疗或预防慢性肾脏病的方法
WO2005102332A1 (ja) 変形性関節症治療剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617